Pulmonary arterial hypertension (PAH) comprises a range of diseases defined by a resting mean pulmonary artery pressure (PAP) of ≥25 mm Hg. Disease pathology is characterized by vasoconstriction and pulmonary vascular remodeling. Treatment options are limited to pharmacological vasodilatation via the prostacyclin, endothelin or nitric oxide pathways, or lung transplantation. Although there have been significant improvements in outcome over the past 2 decades, PAH remains a life shortening condition and survival at 3 years is 68%. There is a clear and pressing need for novel treatment strategies.

See Editor’s Perspective by Leopold

Background—Pulmonary arterial hypertension is a devastating disease with high morbidity and mortality and limited treatment options. Recent studies have shown that pulmonary artery denervation improves pulmonary hemodynamics in an experimental model and in an early clinical trial. We aimed to evaluate the nerve distribution around the pulmonary artery, to determine the effect of radiofrequency pulmonary artery denervation on acute pulmonary hypertension induced by vasoconstriction, and to demonstrate denervation of the pulmonary artery at a histological level.

Methods and Results—Histological evaluation identified a circumferential distribution of nerves around the proximal pulmonary arteries. Nerves were smaller in diameter, greater in number, and located in closer proximity to the luminal aspect of the pulmonary arterial wall beyond the pulmonary artery bifurcation. To determine the effect of pulmonary artery denervation acute pulmonary hypertension was induced in 8 pigs by intravenous infusion of thromboxane A2 analogue. Animals were assigned to either pulmonary artery denervation, using a prototype radiofrequency catheter and generator, or a sham procedure. Pulmonary artery denervation resulted in reduced mean pulmonary artery pressure and pulmonary vascular resistance and increased cardiac output. Ablation lesions on the luminal surface of the pulmonary artery were accompanied by histological and biochemical alteration in adventitial nerves and correlated with improved hemodynamic parameters.

Conclusions—Pulmonary artery denervation offers the possibility of a new treatment option for patients with pulmonary arterial hypertension. Further work is required to determine the long-term efficacy and safety.

Key Words: ablation techniques ■ hypertension, pulmonary ■ nervous system ■ pulmonary artery ■ pulmonary circulation

Pulmonary arterial hypertension (PAH) comprises a range of diseases defined by a resting mean pulmonary artery pressure (PAP) of ≥25 mm Hg. Disease pathology is characterized by vasoconstriction and pulmonary vascular remodeling. Treatment options are limited to pharmacological vasodilatation via the prostacyclin, endothelin or nitric oxide pathways, or lung transplantation. Although there have been significant improvements in outcome over the past 2 decades, PAH remains a life shortening condition and survival at 3 years is 68%. There is a clear and pressing need for novel treatment strategies.

See Editor’s Perspective by Leopold

Autonomic regulation of pulmonary vasculature tone is well recognized, but its role in PAH is less clearly defined. Increased plasma norepinephrine, muscle sympathetic nerve activity, and vessel sympathetic nerve endings have been demonstrated in patients with idiopathic PAH, identifying the neurohormonal axis as a potential therapeutic target.

The sympathetic hyperactivity observed in patients with PAH is partially chemoreflex mediated, but the contribution of other physiological mechanisms cannot be excluded. Baroreceptors at the pulmonary artery bifurcation and along the large pulmonary arteries activate afferent fibers carried in the adventitia, which together with effector fibers in the muscle layer form a pulmo-pulmonary baroreceptor reflex. Surgical
disruption of these fibers has been shown to prevent rises in PAP induced by balloon occlusion; however, the relative contribution of basal sympathetic tone and baroreceptor stimulation to effector fiber activity is unclear. The development of percutaneous methods of arterial denervation now permits investigation of pulmonary artery denervation (PDN) as a treatment for PAH. The benefit of PDN has been shown in preclinical and early clinical studies. The distribution of nerves around the pulmonary arteries, the mechanism of action, and the effect of radiofrequency ablation on the pulmonary artery wall are unknown. The immediate changes in PAP observed in preclinical and clinical studies of PDN cannot be explained by altered remodeling of the distal pulmonary arteries which therefore suggests an effect on vascular constriction. We therefore aimed to examine nerve distribution around the pulmonary arteries, demonstrate the effect of PDN in an acute vasoconstrictive model of pulmonary hypertension (PH), and to show histological evidence of radiofrequency ablation on the nerves within the pulmonary artery adventitia.

**Methods**

### Anatomic Distribution of Nerves Surrounding the Pulmonary Artery

To determine the anatomic relationship of nerve tissue to the pulmonary artery, histological samples were prepared from Yorkshire white swine. Animals were sedated by intramuscular injection of azaperone (6–8 mg/kg) and euthanized by intravenous injection of phenobarbital.

---

**Figure 1.** Pulmonary artery (PA) nerve distribution. A, Volume reconstruction of the pulmonary arteries. Main pulmonary artery plane and right and left pulmonary artery plane represent the levels at which histological sections were taken for evaluation of nerve distribution. B–D, Idealized representation of nerve distribution around the main (B) and right (C) and left pulmonary arteries (D). Gray points represent single nerves, and blue points represent nerve trunks (n=3).
(40 mg/kg) in accordance with The Animals (Scientific Procedures) Act 1986 under UK Home Office Project License 40/3722. The chest was opened via a midline thoracotomy and the pleura and pericardium dissected to expose the heart and great vessels. The inferior vena cava, superior vena cava, and descending aorta were cross-clamped, and the heart and lungs were mobilized and excised en bloc (Figure IA and IB in the Data Supplement).

For anatomic studies of nerve distribution, the pulmonary arteries were excised with local structures in place (Figure IA–IG in the Data Supplement). Tissue was washed in PBS and fixed overnight in 10% formalin. Axial tissue sections were cut post fixation, dehydrated in graded alcohols, and paraffin embedded. Five micrometer sections were mounted and stained with hematoxylin and eosin and S100 protein (Z0311, Dako). Blocks were trimmed to obtain representative axial sections of the main pulmonary artery and the left and right pulmonary arteries beyond the bifurcation (Figure IC–IG in the Data Supplement). Anatomic orientation was determined from local structures. Images were acquired on a scanning microscope (10x objective, Axiocam 506 Color, Zeiss, Germany) and analysis performed in Zen 2 Blue Edition (Zeiss, Germany). Each artery was divided into 4 equal anatomic quadrants (anterior, posterior, medial and lateral, or left and right as appropriate), and S100 and hematoxylin and eosin–stained sections used to identify nerves (Figure IE–IG in the Data Supplement). Diameter, XY coordinate (X, Y), and distance from luminal aspect of the pulmonary artery wall (d) were measured for each nerve. A single reference coordinate (Xr, Yr) was plotted for each quadrant. The angle of the nerve from the reference point was calculated as $\theta = \tan^{-1}((Yn-Yr)/(Xn-Xr))$. The nerve distribution of each quadrant was plotted as ($\theta$, d) using the polar scatter plot function of the Plotly package (https://github.com/ropensci/plotly; http://plot.ly) in the open source programming language R (http://www.R-project.org/). Nerve distribution plots of idealized vessels were constructed from quadrant distribution plots in Photoshop CS6 (Adobe) at the level of the main pulmonary artery and the left and right pulmonary artery.

**Interventional Experimental Study Design**

Eight Yorkshire white pigs (21–27.5 kg) were assigned to PDN or sham procedure. Under anesthesia (intramuscular azaperone, 40 mg/mL at 6 mg/kg; intravenous propofol, 10 mg/mL at 3 mg/kg; and isoflurane, 2% to 3% in 100% O2 via endotracheal tube), left and right heart catheterizations were performed with radiographic guidance (BV Pulsera, Philips). Following baseline hemodynamic measurements, stable thromboxane A2 agonist13 (TxA2, D0400, Sigma-Aldrich) was infused via a 6F sheath in the right internal jugular vein. The dose of infused TxA2, was increased at 5-minute intervals in accordance with a defined protocol (10 μg/mL at 17, 22, 27, 32, and 37 μg/kg per hour) determined from preliminary experiments (data not shown). Each animal received the same escalating dose of TxA2 at the same time interval. Once maximum PAP was attained, TxA2 was discontinued. When PAP returned to baseline, PDN or a sham procedure was performed. To assess the efficacy of PDN, the infusion of TxA2 was repeated post procedure using the same TxA2 challenge protocol.

**Pulmonary hemodynamics were monitored via Swan Ganz catheter (Baxter Healthcare) and systemic arterial pressures via a 6F multipurpose catheter (Medtronic Inc). Cardiac output (CO) was measured by thermodilution and pulmonary vascular resistance (PVR) calculated as PVR=(mean PAP–LVEDP)/CO.**

**Hemodynamic Measurements**

Pulmonary hemodynamics were monitored via Swan Ganz catheter (Baxter Healthcare) and systemic arterial pressures via a 6F multipurpose catheter (Medtronic Inc). Cardiac output (CO) was measured by thermodilution and pulmonary vascular resistance (PVR) calculated as PVR=(mean PAP–LVEDP)/CO.

**Pulmonary Artery Denervation or a sham procedure was performed, and hemodynamic parameters were allowed to return to baseline. The catheter was advanced to the point of denervation and the generator activated; however, no radiofrequency energy was delivered. The second challenge of TxA2 was performed as previously described.**

**Examination of the Pulmonary Artery After PDN**

For histological examination of the pulmonary artery postablation, tissue was excised as previously described, and the pulmonary arteries dissected from surrounding tissue from the pulmonary valve distally. The luminal surface of the pulmonary artery was exposed via an anterior parameters of radiofrequency energy delivery. For each ablation, the PDN catheter, on a 0.014˝ guidewire, was positioned distal to the intended point of denervation. Withdrawal of the guidewire allowed the catheter to reform its resting conformation and apposed the electrode to the luminal aspect of the pulmonary artery. The bifurcation of the main pulmonary artery and the ostium of the basal segmental branches were used as proximal and distal anatomic markers for the procedure. Fluoroscopy and impedance were used to guide catheter positioning and confirm contact of the electrode with the pulmonary artery wall. Continuous monitoring of output, temperature, and impedance was used to monitor and optimize each ablation (Figure II in the Data Supplement). The sham procedure was performed using a dummy catheter that did not deliver radiofrequency energy. The first challenge of TxA2 was performed, and hemodynamic parameters were allowed to return to baseline. The catheter was advanced to the point of denervation and the generator activated; however, no radiofrequency energy was delivered. The second challenge of TxA2 was performed as previously described.

**Figure 2. Experimental model of pulmonary hypertension. A. The dose of thromboxane A2 agonist (TxA2) was increased at 5-minute interval (0–37 μg/kg per hour) and then stopped. Once mean pulmonary artery pressure (mPAP) had returned to baseline, pulmonary artery denervation or a sham procedure was performed, and the TxA2 infusion was repeated. B. Stepped infusion of TxA2 gives a reproducible dose-dependent increase in systolic (sPAP), mean (mPAP) and diastolic PAP (dPAP) (n=8, mean±SEM).**
incision and tissue prepared en face. Ablation points were identified by the presence of blisters on the luminal aspect of the pulmonary artery. Sections were prepared as previously described and stained for hematoxylin and eosin, Alcian blue Elastin/van Gieson (ABEVG), S100 protein (Z0311, Dako), and α-smooth muscle actin (M0851, Dako).14

Statistical Analysis
Data are expressed as mean±SEM. Differences between data sets were assessed by 2-way ANOVA with Sidak’s correction for multiple comparison or Student’s t test as appropriate in Prism 6.0 for Macintosh (GraphPad Software).

Results
Nerve Distribution of the Pulmonary Artery
To map nerve distribution, the pulmonary arteries (main pulmonary artery and left and right pulmonary artery) of 3 Yorkshire white swine were evaluated histologically. At the level of the main pulmonary artery (Figure 1A), there was circumferential distribution of nerves (Figure 1B) that were limited to the anterior and right side by the pericardial reflection and adventitia of the great vessels (Figure 1C and IE in the Data Supplement). The majority of nerves were located between 1 and 3 mm from the endothelial aspect of the pulmonary artery wall and were of a greater diameter than those located more distally (Figure 1A; Figure IH and II in the Data Supplement). Distal to the pulmonary artery bifurcation nerves (Figure 1A) were distributed circumferentially around the right and left pulmonary artery. Nerves were greater in number, smaller in size, and located in closer proximity to the luminal aspect of pulmonary artery wall (<1 mm) than those at the level of the main pulmonary artery (Figure 1B–D; Figure IH and II in the Data Supplement). The number of nerves in close proximity to the right pulmonary artery was greater than the left pulmonary artery (Figure 1C and 1D). Discrete nerve bundles were identified ≥3 mm posterior and right of the main pulmonary artery and posterior and lateral of the right pulmonary artery (Figure 1B and 1C).

TxA2 Induces Acute PH in a Porcine Model
To determine the effect of PDN on PH, an acute TxA2 swine model of PH was established.13 Infusion of TxA2 led to a reproducible, dose-dependent rise in PAP (Figure 2A and 2B). Cessation of TxA2 infusion resulted in the PAP returning to baseline (Figure 2A). Repeated infusion of TxA2 increased PAP in a manner comparable with the initial infusion (Figure 2A), thereby establishing a robust model to test the efficacy of PDN (Figure 3).

Acute Safety
Animals remained hemodynamically stable throughout the procedure. No adverse events were identified as a result of administration of TxA2 or PDN.

PDN Reduces Mean PAP in an Acute Porcine Model of PH
There was no significant difference in hemodynamic response to the first infusion TxA2 between groups selected for PDN or Sham treatment (Figure 4A–4F). Both PDN and Sham-treated animals developed PH in response to TxA2, as demonstrated by mean PAP (mPAP) of >40 mm Hg (Figure 4A). Consistent with the observed change in mPAP, CO was decreased and PVR increased during the induction of PH in both groups (Figure 4C and 4D). Maximum mPAP was comparable between first and second TxA2 challenge in the Sham group;
however, PDN resulted in a reduction in mPAP from first to second TxA₂ challenge in the PDN group and between the Sham and PDN group during the second TxA₂ challenge (Figure 4A). The difference in mPAP was further emphasized by the reduction of area under the curve of mPAP against time from first to second TxA₂ challenge in the PDN group and between the Sham and PDN group during the second TxA₂ challenge (Figure 4B). Consistent with the pressure changes identified, PDN resulted in improved CO and PVR (Figure 4C and 4D). PDN did not alter left ventricular systolic or left ventricular end diastolic pressure (Figure 4E and 4F).

PDN Induces Acute Histological Changes and Reduces Adventitial Nerve Staining

Ablation lesions were visible on the luminal aspect of the pulmonary artery of each animal in the PDN group (Figure 5A), and the number of lesions correlated with hemodynamic response (Figure 5B). Microscopic examination of denervation lesions identified intimal disruption and thrombus (Figure 5C and 5E) with linear elastic laminae (fixed within area of thermal damage), reduced medial thickness (Figure 5C, 5D, 5F, and 5G), and altered adventitial architecture (Figure 5C and 5E). There was also a reduction in the expression of the nerve-associated S100 protein (Figure 5I and 5J). The observed acute histological changes were consistent between animals and between lesions (Figure 5H and 5K).

Discussion

This study maps the location and depth of the nerve distribution of the pulmonary arteries and demonstrates, using a prototype radiofrequency catheter and generator, that PDN alters the structure of nerves supplying the pulmonary arteries and results in a dose-dependent improvement in pulmonary hemodynamics. The acute reduction in PAP achieved with PDN suggests that there is a sympathetic contribution to vasoconstriction in PH that may be therapeutically tractable.

The distribution and function of nerves supplying the pulmonary arteries has been documented in a range of animals; however, data relating anatomic location to nerve depth has not previously been reported. We identified nerve fibers and trunks at the level of the main pulmonary artery and left and right pulmonary arteries with marked variation in vessel wall thickness, nerve depth, and nerve diameter at each level. The depth of histological changes induced by radiofrequency energy delivery varied with anatomic location and wall thickness. In arteries with a greater medial component, such as the aorta or proximal pulmonary artery, there was little or no histological effect of radiofrequency energy delivery on nerve S100 protein staining, indicating that the location and technical parameters of energy delivery are critical to successful PDN. Further anatomic and physiological investigation of nerve distribution and function is clearly required to improve understanding of the therapeutic mechanism of action and enable procedural optimization.
Inflammation, cellular proliferation, and vasoconstriction all drive disease pathology in PAH; however, the contribution of these underlying factors to the burden of disease in an individual patient is not known. Elevated plasma norepinephrine, increased muscle sympathetic nerve activity, and increased vessel sympathetic nerve endings in patients with idiopathic PAH have all been described, thus implicating sympathetic activity in disease. Modulation of the neurohumoral axis in PAH, using pharmacological and device-based therapies, has shown benefit in experimental and early human studies. Further work is required to understand the role in disease pathology and establish the therapeutic mechanism. Previous PDN studies have demonstrated efficacy using a balloon occlusion model, however, the mechanism by which PH is induced in that model remains controversial. Balloon occlusion is thought to cause an increase in PAP through activation of a pulmo-pulmonary baroreflex, but the extent to which this reflex contributes to human disease is unknown. Vasoconstriction is a fundamental mediator of disease pathology in PAH. We therefore used a vasoconstriction-based model of PH and have demonstrated that PDN reduced PAP and PVR and increased CO, with a limited reduction of systemic blood pressure. Our findings suggest that the innervation of the pulmonary vasculature contributes to PH in disease models beyond balloon occlusion. Although our findings do not fully replicate the complete prevention or reversal of PH previously reported, the improvement in pulmonary hemodynamics achieved would be clinically meaningful.

Figure 5. A. En face preparation of the pulmonary artery. Arrows indicate denervation lesions in the right pulmonary artery. B. Change in mean pulmonary artery pressure (mPAP) between first and second infusion of thromboxane A agonist (TxA) plotted against the number of visible ablation lesions. C–E, Alcian blue Elastin/van Gieson (ABEVG)-stained artery sections (scale bar: 500 μm). C, Control pulmonary artery, D, denervation lesion in the pulmonary artery, and E, denervation lesion in the aorta. F and G, Smooth muscle actin-stained pulmonary artery sections (scale bar: 500 μm). F, Control and (G) denervation lesion. H, The acute effect of pulmonary artery denervation (PDN) on wall medial thickness. I and J, S100 protein-stained sections showing nerves in the pulmonary artery adventitia (scale bar 20 μm). I, Control and (J) denervation lesion. K, The acute effect of PDN on nerve S100 protein staining (n=5, mean±SEM, *P<0.05, paired Student t test).
Although PDN has shown promising early results, it is critically important that the mechanistic effects of intervention are fully evaluated in the context of chronic disease.

Limitations
PH in the TxA₂ model is induced by acute vasoconstriction and not by progressive pulmonary vascular remodeling. The acute nature of the experiment precluded the evaluation of long-term effect on pulmonary hemodynamics and vessel histology. Although vasoconstriction plays a role in disease pathology and is a therapeutic target for the treatment of PAH, the improved hemodynamics demonstrated in this study may not translate directly to human disease.

Conclusions
In an acute vasoconstriction-based model of PH, we have provided a detailed description of the distribution of nerves in the proximal pulmonary vasculature. We have also demonstrated the efficacy of PDN and described the associated histological and biochemical changes. Further studies are required to optimize the PDN procedure and to investigate the safety and the long-term efficacy of intervention before large clinical trials in patients are considered.

Acknowledgments
We would like to acknowledge Ms Tracy Sanderson (Department of Histopathology, Sheffield Teaching Hospitals NHS Trust) for assistance with preparation of histological sections, and Dr Rachael Elder (Department of Chemical and Biological Engineering, University of Sheffield), Mr James Iremonger, and Mr Adam Braithwaite (Department of Cardiovascular Science, University of Sheffield) for assistance with representation of nerve distribution data.

Sources of Funding
Medical Research Council Confidence in Concepts (Dr Rothman, Gunn, and Lawrie: MC/PC/12022) and Clinical Research Training Fellowship (Dr Rothman: MR/K002406/1) awards, and a British Heart Foundation Senior Basic Scientist Fellowship (Dr Lawrie: FS/13/48/30453) award. Catheters and generator were provided by Heart Foundation Senior Basic Scientist Fellowship (Dr Lawrie: MC/PC/12022) and Clinical Research Training Medical Research Council Confidence in Concepts (Drs Rothman, and consulting fees from SoniVie Ltd. W. Chang is an employee of Medtronic Inc via an External Research Program award (Dr Rothman). FS/13/48/30453) award. Catheters and generator were provided by Heart Foundation Senior Basic Scientist Fellowship (Dr Lawrie: MC/PC/12022) and Clinical Research Training Medical Research Council Confidence in Concepts (Drs Rothman, and consulting fees from SoniVie Ltd. W. Chang is an employee of Medtronic Inc via an External Research Program award (Dr Rothman).

Disclosures
Dr Rothman has received research support from Medtronic Inc and consulting fees from SoniVie Ltd. W. Chang is an employee of Medtronic Inc. The other authors report no conflicts.

References
1. Hurmid J, Confidite R, Elliot CA, Davies C, Hill C, Wild JM, Capener D, Septon P, Hamilton N, Armstrong JJ, Billings C, Lawrie A, Sabroe I, Akil M, O’Toole L, Kiely DG. ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a Referral centre. Eur Respir J. 2012;39:945–955. doi: 10.1183/09031936.00078411.
2. Galé N, Corris PA, Frost A, Grgic RE, Granton J, Jing ZC, Klepetko W, McGooin MD, McLaughlin VV, Preston IR, Rubin LJ, Sandoval J, Seeger W, Keogh A. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62(25 suppl):D60–D72. doi: 10.1016/j.jacc.2013.10.031.
3. Nootens M, Kaufmann E, Rector T, Toher C, Judd D, Francis GS, Rich S. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol. 1995;26:1581–1585. doi: 10.1016/0735-1097(95)00399-1.
4. Mak S, Witte KK, Al-Hesayen A, Granton JJ, Parker JD. Cardiac sympathetic activation in patients with pulmonary arterial hypertension. Am J Physiol Regul Integr Comp Physiol. 2012;302:R1153–R1157. doi: 10.1152/ajpregu.00652.2011.
5. Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de Borne P. Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation. 2004;110:1308–1312. doi: 10.1161/01.CIR.0000140724.90898.D3.
6. Ciarka A, Doan V, Velez-Roa S, Naeije R, van de Borne P. Prognostic significance of sympathetic nervous system activation in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010;181:1269–1275. doi: 10.1164/rcrm.200912-1856OC.
7. Roehl AB, Steendijk P, Baumert JH, Schnoor J, Rossaint R, Hein M. Pulmonary hypertension. J Exp Med. 2011;209:191–1935. doi: 10.1084/jem.20112716.
8. Juratsch CE, Jengo JA, Castagna J, Laks MM. Experimental pulmonary hypertension produced by surgical and chemical denervation of the pulmonary vasculature. Chest. 1980;77:525–530.
9. Osorio J, Russek M. Reflex changes on the pulmonary and systemic pressures elicited by stimulation of baroreceptors in the pulmonary artery. Circ Res. 1962;10:664–667.
10. Baylen BG, Emmanouilides GC, Juratsch CE, Yoshida Y, French WJ, Cleary JM. Main pulmonary artery distention: a potential mechanism for acute pulmonary hypertension in the human newborn infant. J Pediatr. 1980;96(3 pt 2):540–544.
11. Chen SL, Zhang YJ, Zhou L, Xie DJ, Zhang FF, Jia HB, Wong SS, Kwan TW. Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo. EuroIntervention. 2013;9:269–276. doi: 10.4244/EIJY12A43.
12. Chen SL, Zhang FF, Xu J, Xie DJ, Zhou L, Nguyen T, Stone GW. Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension). J Am Coll Cardiol. 2013;62:1092–1100. doi: 10.1016/j.jacc.2013.05.075.
13. Roehl AB, Steendijk P, Baumert JH, Schnoor J, Rossaint R, Hein M. Comparison of 3 methods to induce acute pulmonary hypertension in pigs. Comp Med. 2009;59:280–286.
14. Hameed AG, Arnold ND, Chamberlain J, Pickworth JA, Paiva C, Dawson S, Cross S, Long L, Zhao L, Morrell NW, Crossman DC, Newman CM, Kiely DG, Francis SE, Lawrie A. Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension. J Exp Med. 2012;209:1919–1935. doi: 10.1084/jem.20112716.
15. Kummer W. Pulmonary vascular innervation and its role in responses to hypoxia: size matters! Proc Am Thorac Soc. 2011;8:471–476. doi: 10.1513/pats.201101-013MW.
16. Tudor RM, Archer SL, Dorfmüller P, Erzurum SC, Guignabert C, Michelakis E, Rabinovich M, Schermuly R, Stenmark KR, Morrell NW. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 suppl):D4–D12. doi: 10.1016/j.jacc.2013.10.025.
17. de Man FS, Handoko ML, van Ballegoij JJ, Schalij I, Bogaards SJ, Postmus PE, van der Velden J, Westerhof N, Paulus WJ, Vonk-Noordegraaf A. Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. Circ Heart Fail. 2012;5:97–105. doi: 10.1161/CIRCHEARTFAILURE.111.964949.